title: The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011.
abstract: OBJECTIVE
  To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment.
  
  
  METHODS
  This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature.
  
  
  RESULTS
  A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference.
  
  
  CONCLUSIONS
  We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients.
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Cinthia Leite Frizzera Borges
authors.initials: CL
authors.lastname: Bognar
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Sergio Daniel
authors.initials: SD
authors.lastname: Simon
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Rene Claudio
authors.initials: RC
authors.lastname: Gansl
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Roberto
authors.initials: R
authors.lastname: Abramoff
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Aisen
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Gilberto de Lima
authors.initials: Gde L
authors.lastname: Lopes Junior
authors.affiliation: Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
authors.forename: Oren
authors.initials: O
authors.lastname: Smaletz
authors.affiliation: Universidade de São Paulo, São Paulo, SP, Brazil.
authors.forename: Stela Verzinhasse
authors.initials: SV
authors.lastname: Peres
authors.affiliation: Centro Paulista de Oncologia, São Paulo, SP, Brazil.
authors.forename: Jacques
authors.initials: J
authors.lastname: Tabacof
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001938:Brazil; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D066246:ErbB Receptors / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D006769:Hospitals, General; D006777:Hospitals, Proprietary; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D017678:Sex Distribution; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors